ClinicalTrials.Veeva

Menu

Bioavailability of Omega-3 Food Supplement in Healthy Subjects

P

Pronova

Status and phase

Completed
Phase 1

Conditions

Biological Availability

Treatments

Dietary Supplement: Pronovum PRF-041
Dietary Supplement: Eskimo-3
Dietary Supplement: Pronova Pure 150:500 EE EU
Dietary Supplement: Pronovum PRF-037

Study type

Interventional

Funder types

Industry

Identifiers

NCT02376608
CTN00714101

Details and patient eligibility

About

The study will evaluate the relative bioavailability of Pronovum PRF-037 and Pronovum PRF-041 with PronovaPure 150:150 EE EU and Eskimo-3 (500 mg omega-3 acid triglyceride containing 80 mg EPA and 50 mg DHA per gram oil) in healthy subjects.

Enrollment

24 patients

Sex

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • males or females
  • any ethnic origin
  • BMI 18.5 - 30.0 kg/m2
  • generally in good health
  • signed informed consent

Exclusion criteria

  • males or females not willing to use appropriate contraception
  • prescribed systemic or topical medication within 14 days and slow release medication considered to be active within 14 days.
  • omega-3 fatty acids or fish oil within 2 weeks of dosing.
  • any non-prescribed systemic or topical medication including herbal remedies and vitamin/mineral supplements within 7 days
  • any medication incl. St.John's Worth known to chronically alter drug absorption/elimination within 30 days
  • Subjects still present in clinical study or in the past 3 months
  • recent blood donation
  • drug allergy or significant allergic disease
  • allergic or hypersensitivity to omega-3 acids, fish, soya, oleic acid, sesame oil or other constituents in pharma preparation
  • high consumption of alcohol
  • high consumption of tobacco
  • hepatitis or HIV
  • vegetarians
  • earlier participated in or withdrawn from the study
  • not willing to follow dietary restrictions
  • frequent occurence of migraine attacks
  • subjects that should not participate according to investigator

Trial design

24 participants in 4 patient groups

Pronova Pure 150:500 EE EU
Active Comparator group
Description:
2 × PronovaPure 150:500 EE EU
Treatment:
Dietary Supplement: Pronova Pure 150:500 EE EU
Dietary Supplement: Eskimo-3
Dietary Supplement: Pronovum PRF-037
Dietary Supplement: Pronovum PRF-041
Pronovum PRF-037
Active Comparator group
Description:
2 × Pronovum PRF-037
Treatment:
Dietary Supplement: Pronova Pure 150:500 EE EU
Dietary Supplement: Eskimo-3
Dietary Supplement: Pronovum PRF-037
Dietary Supplement: Pronovum PRF-041
Pronovum PRF-041
Active Comparator group
Description:
2 × Pronovum PRF-041
Treatment:
Dietary Supplement: Pronova Pure 150:500 EE EU
Dietary Supplement: Eskimo-3
Dietary Supplement: Pronovum PRF-037
Dietary Supplement: Pronovum PRF-041
Eskimo-3
Active Comparator group
Description:
3 × Eskimo-3
Treatment:
Dietary Supplement: Pronova Pure 150:500 EE EU
Dietary Supplement: Eskimo-3
Dietary Supplement: Pronovum PRF-037
Dietary Supplement: Pronovum PRF-041

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems